MedTrace Logo

Etoricoxib Prescribing Patterns and Adverse Events of Interest in Primary Care in the United Kingdom (MK-0663-162 AM1)

NCT01685424 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 79189

Last updated 2022-02-18

No results posted yet for this study

Summary

This postmarketing study was conducted to describe prescribing patterns for etoricoxib (ARCOXIA®) in General Practice and describe the incidence of selected adverse events recorded in the United Kingdom (UK) Medicines and Health Care Products Regulatory Agency (MHRA) General Practice Research Database (GPRD).

Conditions

Interventions

DRUG

Etoricoxib

As per routine clinical practice in the United Kingdom

Sponsors & Collaborators

  • Organon and Co

    lead INDUSTRY

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2015-03-01
Completion
2015-03-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01685424 on ClinicalTrials.gov